Intravenous Immunoglobulin-Associated Severe Hemolytic Anemia

Area of Science:

• Immunology
• Hematology
• Neurology

Background:

• Intravenous immunoglobulin (IVIG) is a widely used therapy for various immune-related disorders.
• While generally safe, IVIG can cause hematological adverse reactions, including hemolytic anemia.
• Severe symptomatic hemolytic anemia is a rare but serious complication of IVIG therapy.

Observation:

• A case report details a 66-year-old male patient who developed severe symptomatic hemolytic anemia post-IVIG treatment for acute inflammatory demyelinating polyneuropathy (AIDP).
• The patient presented with known risk factors for IVIG-induced hemolytic anemia: non-O blood group, high cumulative IVIG dose, and an underlying autoimmune condition.

Findings:

• The patient's non-O blood group, high cumulative IVIG dose, and autoimmune condition placed him at significant risk.
• This case highlights the potential for severe, symptomatic hemolytic anemia even in patients receiving IVIG for appropriate indications.

Implications:

• Clinicians should maintain a high index of suspicion for severe hemolytic anemia in patients receiving IVIG.
• Close monitoring of patients with identified risk factors is essential for early diagnosis and management of this adverse reaction.
• Awareness and vigilance can prevent severe complications associated with IVIG-induced hemolysis.